PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: GenericsWeb Pty Ltd | Ark Patent Intelligence

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

GenericsWeb Analyses Fosaprepitant and its Surrounding Patent Landscape - GenericsWeb.com - Emend (Fosaprepitant) – an attractive opportunity for makers of generics - ArkPatentIntelligence.com
GenericsWeb Analyses Fosaprepitant and its Surrounding Patent Landscape - GenericsWeb.com

 

NewswireToday - /newswire/ - Sydney, New South Wales, Australia, 2010/11/29 - Emend (Fosaprepitant) – an attractive opportunity for makers of generics - ArkPatentIntelligence.com.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

GenericsWeb, a leader in established pharmaceutical patent searching and analysis, recently published an article based on its proprietary patent intelligence for Emend®/Ivemend® (Fosaprepitant), Merck's drug for the prevention of chemotherapy induced nausea and vomiting. The article analyses the surrounding patent landscape, highlighting the need for comprehensive, up-to-date information in the development of launch strategies that minimise the cost of litigation and understanding the barriers to launch as to receive the benefits of your generic product being first to market.

Key findings of the article include:

• In most countries where Emend is marketed, the data and market exclusivity will expire before patent expiry thus will not affect the date of generic competition.

• Patents protecting the use of the type of active ingredient (Neurokinin-1 receptor antagonist) would expire at the latest by July 2013. US patents in this family are currently the subject of litigation in regard to Sandoz’ paragraph IV certified ANDA for Aprepitant (Emend).

• Patents protecting the Fosaprepitant molecule would likely continue to be in force until 2020 (2019 in the US) when patent term extensions or SPCs expire (assuming pending SPC applications are granted).

Fosaprepitant, a selective Neurokinin-1 (NK-1) receptor antagonist and substance P inhibitor is an anti-emetic agent marketed by Merck under the brand name Emend. Available as a powder for injection, Fosaprepitant it is a prodrug of the active ingredient Aprepitant found in the oral dosage form sharing the same brand name. Sales of Emend exceeded US$300 million in 2009 and continue with double digit growth in 2010.

About GenericsWeb – THE SEARCH IS OVER

GenericsWeb (genericsweb.com), the leader in pharmaceutical patent analysis and searching holds an impeccable track record in providing quality patent information, and has allowed numerous pharmaceutical companies to successfully navigate intellectual property hazards. GenericsWeb is headquartered in Sydney, Australia, with offices in North America and Europe. All staff are highly skilled and experienced internationally and have extensive experience in pharmaceutical sciences and patent searching.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: GenericsWeb Pty Ltd | Ark Patent Intelligence

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


GenericsWeb Analyses Fosaprepitant and its Surrounding Patent Landscape - GenericsWeb.com

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: Yoann Bretonnet - GenericsWeb.com 
+61(2) 9262 7696 info[.]genericsweb.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any GenericsWeb Pty Ltd | Ark Patent Intelligence securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From GenericsWeb Pty Ltd | Ark Patent Intelligence / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

BD Veritor™ System Meets FDA’s New Performance Requirements for Rapid Influenza Antigen Detection Tests
MDxHealth Announces Agreement with Istituto Diagnostico Varelli for Distribution of SelectMDx Throughout Central-South Italy
Sub-Sahara Africa - Increase in Western Lifestyles Leads to Dire Need for Chronic Prescription Drugs Finds Frost & Sullivan
BD Initiates New Industry Alliance to Combat Rising Opioid Crisis
BTG and Society of Interventional Oncology to Explore Role of Minimally Invasive Therapies in Immuno-oncology
Ipsen to Acquire a Portfolio of Select Consumer Healthcare Products from Sanofi
BD Announces Early Access Program for BD Resolve™ Single-Cell Analysis Platform
Precision Medicine Unlocks the Future of Targeted Therapy in the Global Healthcare Industry Finds Frost & Sullivan
Sciformix Corporation Receives Prestigious 2017 Global Outsourcing Customer Service Leadership Award from Frost & Sullivan
Arven Pharmaceuticals Selects GE Healthcare’s FlexFactory to Improve Turkish and Regional Access to Biopharmaceuticals
Ipsen to Acquire Primary Care Platform in Italy from Akkadeas Pharma
Cost-Containment and Client-Centric Services Catalyse European Custom Procedure Trays and Packs Market Finds Frost & Sullivan
New BD Institute for Medication Management Excellence Aims to Improve Patient Safety and Outcomes through Collaboration
New Varicose Vein Treatment Offers Minimally Invasive Non Surgical Procedure to Canadians
Greenphire and Exostar Partner to Deliver Seamless, Secure Access to Clinical Research Site Payment Solution

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  NAKIVO, Inc.

Visit  JobsWare.com





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)